SG11202112136RA - Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody - Google Patents
Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibodyInfo
- Publication number
- SG11202112136RA SG11202112136RA SG11202112136RA SG11202112136RA SG11202112136RA SG 11202112136R A SG11202112136R A SG 11202112136RA SG 11202112136R A SG11202112136R A SG 11202112136RA SG 11202112136R A SG11202112136R A SG 11202112136RA SG 11202112136R A SG11202112136R A SG 11202112136RA
- Authority
- SG
- Singapore
- Prior art keywords
- lag
- administration
- bispecific antibody
- dosage regimes
- regimes
- Prior art date
Links
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1906807.1A GB201906807D0 (en) | 2019-05-14 | 2019-05-14 | Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody |
| GB201914040A GB201914040D0 (en) | 2019-09-30 | 2019-09-30 | Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody |
| GBGB2000318.2A GB202000318D0 (en) | 2020-01-09 | 2020-01-09 | Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody |
| PCT/EP2020/063529 WO2020229626A1 (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112136RA true SG11202112136RA (en) | 2021-11-29 |
Family
ID=70775359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112136RA SG11202112136RA (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220275092A1 (en) |
| EP (1) | EP3969477A1 (en) |
| JP (1) | JP2022533578A (en) |
| KR (1) | KR20220008316A (en) |
| CN (1) | CN114206939A (en) |
| AU (1) | AU2020275209A1 (en) |
| BR (1) | BR112021022831A2 (en) |
| CA (1) | CA3139003A1 (en) |
| IL (1) | IL287979A (en) |
| MX (1) | MX2021013943A (en) |
| SG (1) | SG11202112136RA (en) |
| WO (1) | WO2020229626A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109311993B (en) | 2016-06-20 | 2022-12-20 | F-星治疗有限公司 | LAG-3 binding element |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| JP7360440B2 (en) | 2018-07-12 | 2023-10-12 | エフ－スター セラピューティクス リミテッド | Antibody molecules that bind to PD-L1 and CD137 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| WO2020011966A1 (en) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind cd137 and ox40 |
| PH12023552704A1 (en) * | 2021-03-31 | 2024-02-19 | Merus Nv | Novel multispecific antibodies |
| GB202304278D0 (en) | 2023-03-23 | 2023-05-10 | F Star Therapeutics Ltd | Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3472207T1 (en) | 2016-06-20 | 2021-04-30 | F-Star Delta Limited | Binding molecules that bind PD-L1 and LAG-3 |
| BR112019018759A2 (en) * | 2017-05-30 | 2020-05-05 | Bristol-Myers Squibb Company | compositions comprising a combination of an anti-lag-3 antibody, an inhibitor of the pd-1 pathway, and an immunotherapeutic agent |
| DK3631454T3 (en) * | 2017-05-30 | 2023-12-04 | Bristol Myers Squibb Co | TREATMENT OF LAYER-3 POSITIVE TUMORS |
-
2020
- 2020-05-14 CN CN202080051441.8A patent/CN114206939A/en active Pending
- 2020-05-14 BR BR112021022831A patent/BR112021022831A2/en unknown
- 2020-05-14 CA CA3139003A patent/CA3139003A1/en active Pending
- 2020-05-14 SG SG11202112136RA patent/SG11202112136RA/en unknown
- 2020-05-14 US US17/610,873 patent/US20220275092A1/en not_active Abandoned
- 2020-05-14 WO PCT/EP2020/063529 patent/WO2020229626A1/en not_active Ceased
- 2020-05-14 MX MX2021013943A patent/MX2021013943A/en unknown
- 2020-05-14 AU AU2020275209A patent/AU2020275209A1/en active Pending
- 2020-05-14 KR KR1020217040782A patent/KR20220008316A/en active Pending
- 2020-05-14 JP JP2021566974A patent/JP2022533578A/en active Pending
- 2020-05-14 EP EP20726768.3A patent/EP3969477A1/en not_active Withdrawn
-
2021
- 2021-11-10 IL IL287979A patent/IL287979A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3139003A1 (en) | 2020-11-19 |
| US20220275092A1 (en) | 2022-09-01 |
| JP2022533578A (en) | 2022-07-25 |
| MX2021013943A (en) | 2022-01-04 |
| CN114206939A (en) | 2022-03-18 |
| KR20220008316A (en) | 2022-01-20 |
| BR112021022831A2 (en) | 2022-01-18 |
| IL287979A (en) | 2022-01-01 |
| AU2020275209A1 (en) | 2021-12-23 |
| EP3969477A1 (en) | 2022-03-23 |
| WO2020229626A1 (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287979A (en) | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody | |
| GB2594345B (en) | Single dosage shampoo | |
| ZA202004907B (en) | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| IL290256A (en) | Anti-pd-1 antibody and pharmaceutical use thereof | |
| IL278889A (en) | Dosing regimen for the treatment of pi3k related disorders | |
| EP3975975A4 (en) | CLOSED SYSTEM PHARMACEUTICAL DELIVERY DEVICES FOR SOLID DOSAGE FORMS | |
| PL3738800T3 (en) | Apparatus for dispensing multicomponent adhesives onto a granular mixture, and method of dispensing and using the apparatus | |
| IL285134A (en) | Therapeutic antibody formulation | |
| EP3784214A4 (en) | Liquid oral pharmaceutical dosage form | |
| IL281958A (en) | Pharmaceutical compositions comprising bispecific anti-cd37 antibodies | |
| LT4058148T (en) | Dosing regimen for anti-bcma agents | |
| IL291432A (en) | Dosing for anti-tryptase antibodies | |
| IL281398A (en) | Process for the preparation of a coated solid pharmaceutical dosage form | |
| HK40071349A (en) | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody | |
| GB201914040D0 (en) | Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody | |
| GB202000318D0 (en) | Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody | |
| GB201906807D0 (en) | Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody | |
| EP4055061A4 (en) | Dosage regimen for anti-egfrviii agents | |
| PL3972905T3 (en) | DOSING DEVICE FOR ADMINISTRATION OF THE INFUSION PRODUCT | |
| GB2589119B (en) | Dosage dispensing system | |
| PL3934814T3 (en) | Dispenser for discharging flowable compounds | |
| HK40049719A (en) | Dosing regimen for the treatment of pi3k related disorders | |
| HK40066344B (en) | Ox40/pd-l1 bispecific antibody | |
| HK40074182A (en) | Dosing regimen for anti-dll3 agents | |
| HK40113969A (en) | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |